AUSTIN, Texas, Sept. 8 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that initial results from a study conducted at the NMI Natural and Medical Sciences Institute at the University of Tubingen in Germany demonstrate that its MAGPIX® system provides more cost effective and efficient results than a conventional microtiter plate based ELISA method.
"These initial results demonstrate why MAGPIX could be a good choice for every research laboratory," said Dr. Thomas Joos, the head of the Biochemistry Department at the Natural and Medical Sciences Institute. "The system is a great choice for labs seeking one platform that allows the efficiency of multiplexing as well as the ability to run single tests, as needed. It can help labs save resources, increase efficiency and maximize results."
The NMI Natural and Medical Sciences Institute performed a comparative study between the recently launched MAGPIX system and a conventional ELISA method. The study utilized an assay for soluble tumor necrosis factor receptor II to compare the analytical methods using several parameters including optimal detection antibody concentration, dynamic range and assay sensitivity, sample measurement, intra- and inter-assay precision, parallelism, and dilution linearity. In addition to analytical performance, a time and motion analysis, and a cost comparison was performed.
The findings from this initial study demonstrate that MAGPIX provides accurate assay results at costs of as much as half of the microtiter plate ELISA method with equivalent sensitivity. While total assay and hands-on time for MAGPIX and ELISA were similar, MAGPIX is capable of producing up to 50 results in the same amount of time as one ELISA sample while requiring the same amount of sample material.
"We are very pleased with the findings of Dr. Joos's study at NMI, demonstrating strong performance of MAGPIX in relation to conventional ELISA testing," said Patrick J. Balthrop, president and CEO of Luminex. "These initial data highlight the importance of MAGPIX as a scientific tool for any lab seeking to enhance productivity and bring the power of multiplexing to their day-to-day research."
Luminex's MAGPIX system is a compact analytical instrument capable of performing up to 50 tests on a single sample providing nearly 5,000 data points in under an hour. The easy-to-use and simple-to-deploy instrument was designed to meet the needs of scientists and researchers who have not been able to take advantage of the power of multiplexing because of resource or space limitations.
Based on Luminex's xMAP® Technology, MAGPIX provides fast, accurate and easily reproducible results and saves laboratory time and resources. Like all of Luminex's instruments, it is versatile and flexible and can be used to analyze both nucleic acids and proteins, making it applicable in many research settings.
For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix.
About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.Luminex Contacts:Harriss T. Currie, 512-219-8020Vice President, Finance and Chief Financial Officerhcurrie@luminexcorp.comMimi L. Torrington, 512-219-8020Director of Investor Relationsmtorrington@luminexcorp.comMedia:Nicole L. Cottrill, firstname.lastname@example.org
|SOURCE Luminex Corporation|
Copyright©2010 PR Newswire.
All rights reserved